Engineered immune cells unleashed to battle tough leukemia
NCT ID NCT02146924
Summary
This early-stage study is testing a new type of cell therapy for adults with a high-risk or returning form of acute lymphoblastic leukemia (ALL). Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and infuse them back after a short course of chemotherapy. The main goals are to find the safest dose and see what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.